1717 Langhorne Newtown Road
Suite 300
Langhorne, PA 19047
United States
(512) 614-1848
https://www.savarapharma.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 37
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Matthew Pauls J.D., M.B.A. | Chairman & CEO | 970k | N/A | 1971 |
Mr. David L. Lowrance CPA | CFO, Chief Administrative Officer & Secretary | 667,4k | N/A | 1968 |
Mr. Scott L. Wilhoit | Executive Vice President of Global Commercial | N/A | N/A | 1963 |
Dr. Brian Robinson M.D. | Senior VP of Global Medical Affairs | N/A | N/A | N/A |
Dr. Yasmine Wasfi M.D., Ph.D. | Senior VP & Head of Clinical Development | N/A | N/A | N/A |
Dr. Siddharth J. Advant Ph.D. | Executive Vice President of Global Technical Operations | N/A | N/A | N/A |
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Langhorne, Pennsylvania.
El ISS Governance QualityScore de Savara Inc., a día 1 de mayo de 2024, es 4. Las puntuaciones base son Auditoría: 4; Tablero: 6; Derechos de los accionistas: 1; Compensación: 7.